FDA's Transparency Initiative Enters The "What Is The Right Thing To Do" Phase: An Interview With Principal Deputy Commissioner Sharfstein
Executive Summary
In June, FDA launched an internal Transparency Task Force to evaluate how to make the agency's decision-making process more accessible to the public. The agency held two public meetings and solicited comments from the public; the docket closed Nov. 6. FDA Principal Deputy Commissioner Joshua Sharfstein, who chairs the task force, spoke to "The Pink Sheet" about its initial findings
You may also be interested in...
FDA Transparency Initiative Sees No Clear Path To Releasing Documents, Woodcock Indicates
FDA is finding the possible release of its voluminous documents one of the more challenging aspects of the effort to make its operations and decisions more open to the public, and the challenges are both in policies and resources, FDA's Janet Woodcock says
FDA Transparency Initiative Sees No Clear Path To Releasing Documents, Woodcock Indicates
FDA is finding the possible release of its voluminous documents one of the more challenging aspects of the effort to make its operations and decisions more open to the public, and the challenges are both in policies and resources, FDA's Janet Woodcock says
FDA Transparency Initiative Sees No Clear Path To Releasing Documents, Woodcock Indicates
Requirements to redact proprietary information from documents, make them accessible to the disabled, and other challenges would greatly tax FDA staff, FDA's Janet Woodcock says.